Reports and Findings (Published Research)

Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 years

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle

BCG vaccination to Reduce the impact of COVID-19 in Australian healthcare workers following Coronavirus Exposure (BRACE) Trial

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle

ATOMIC Ears: A Phase IIB randomised controlled trial to assess safety, tolerability and acceptability of a 5-day Dornase alfa treatment as an adjunct therapy to ventilation tube insertion for otitis media in children

Chris Jennifer Lea-Ann Peter Ruth Brennan-Jones Kent Kirkham Richmond Thornton PhD RN PhD MBBS MRCP(UK) FRACP PhD Head, Ear and Hearing Health Clinical Research Manager Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,

A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of age

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle

A phase 3, multicenter, randomized, double-blind, active-comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants (PNEU-PED-EU-1)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle

A phase 3, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety and tolerability of V114 in healthy infants (PNEULINK)

Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical Research Manager Head, Vaccine Trials Group Jennifer completed her Diploma of Nursing in 1986 at Fremantle

Young Minds Matter

Young Minds Matter is the largest survey of child and adolescent mental health and wellbeing ever conducted in Australia.

WA Department of Health Merit Awards - Project - Improving Aboriginal health disparities: the influence of education, child protection and justice systems over time and across generations

This project is a partnership between researchers, the Aboriginal community and government to provide evidence for policy addressing major health priority areas for Aboriginal children and families.

Tassie Kids: Pathways

Tassie Kids will bring together information about what early childhood services families use across the first five years of a child’s life.

Developing a protocol for a national study of bullying prevalance in school-aged children

The Kids Research Institute Australia's Human Capability Team has been asked by the Commonwealth Department of Education, Skills and Employment (DESE) to prepare a methodology and project plan to conduct a nationally-representative survey of bullying prevalence among children and young people in Years 4–10.